Evidence map›Paper›PMID 35948057›Full record

ArticleACS infectious diseases2022

Calcimycin Inhibits

Anil Mathew Tharappel, Zhong Li, Yan Chun Zhu, Xiangmeng Wu, Sudha Chaturvedi, Qing-Yu Zhang, Hongmin Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anil Mathew TharappelDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson Arizona 85721-0207, United States.
Zhong LiDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson Arizona 85721-0207, United States.
Yan Chun ZhuWadsworth Center, New York State Department of Health, Albany, New York 12208, United States.
Xiangmeng WuDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson Arizona 85721-0207, United States.
Sudha ChaturvediWadsworth Center, New York State Department of Health, Albany, New York 12208, United States.
Qing-Yu ZhangDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson Arizona 85721-0207, United States.
Hongmin LiDepartment of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson Arizona 85721-0207, United States.ORCID 0000-0002-8684-5308
New York State Department of Health · USUniversity of Arizona · US

Funding

High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosisR01AI161845 · NIAID · UNIVERSITY OF ARIZONA · PI AVRAM, DORINA, LI, HONGMIN · 2021 to 2025
$3.9M
High throughput screening of orthosteric inhibitors of flavivirus proteaseR01AI131669 · NIAID · WADSWORTH CENTER · PI LI, HONGMIN · 2018 to 2022
$2.6M
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungiR01AI140726 · NIAID · WADSWORTH CENTER · PI LI, HONGMIN · 2019 to 2022
$2.4M
High throughput screening of orthosteric inhibitors of flavivirus proteaseR56AI131669 · NIAID · WADSWORTH CENTER · PI LI, HONGMIN · 2017 to 2017
$524k
Neutralizing nanobodies as therapeutics for Dengue virusR21AI140406 · NIAID · WADSWORTH CENTER · PI LAWRENCE, DAVID A, LI, HONGMIN · 2018 to 2019
$460k
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical LibrariesR21AI141178 · NIAID · WADSWORTH CENTER · PI LI, HONGMIN · 2019 to 2020
$441k
NIAID NIH HHS R01 AI131669NIAID NIH HHS R01 AI140726NIAID NIH HHS R01 AI161845NIAID NIH HHS R21 AI140406NIAID NIH HHS R21 AI141178NIAID NIH HHS R56 AI131669
6 · The paper itself

Abstract

Drug resistance is a significant concern in the treatment of diseases, including cryptococcosis caused by

Indexed as

CryptococcosisCryptococcus neoformansAnimalsAntifungal AgentsCalcimycinFungal ProteinsHumansInteinsMiceSequence AlignmentAntifungal AgentsCalcimycinFungal ProteinsAntifungalsCalcimycinCryptococcosisIntein splicing inhibitorsPrp8-intein

Identifiers

PMID35948057
PMCPMC9464717
OpenAlexW4291020713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.